CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval For Highly Selective PDE4B Inhibitor SYH2059 Powder For Inhalation In The U.S

Source: marketscreener The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.